Xenon Pharmaceuticals Inc. XENE
805 filings, 6 in the last 30 days
SEC filing indexWhat the 8-Ks said
2 events in the last 3 years: the officer, auditor, restatement, cyber, restructuring, listing, impairment and debt items. One line each, the filing's own words.
- Mar 5, 2025 Auditor changeChanged the accounting firm that audits it 8-K item 4.01 · all documents
- Feb 27, 2025 CEO, CFO, COO or CAOCFO change “Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.” 8-K item 5.02 · all documents
From the SEC filing index and the text of each 8-K. A line appears only when the 8-K names one of these items; for item 5.02 only a move of the CEO, CFO, COO or chief accounting officer. Older 8-Ks may have no text downloaded, so they show no quote.
Late filings, 8-K notices and going concern
None found in the last 2 years
-
Late filing notices (NT 10-K, NT 10-Q)No notice in the last 2 years.
-
8-K notices: listing, impairment, debt triggerNo item 3.01, 2.06 or 2.04 in the last 2 years.
-
Going-concern language in the 10-KNo statement of substantial doubt in the latest 10-K.
Facts to read in the filing, not a verdict: many companies with one of these carry on normally, and a company with neither can still have problems.
Every filing on one line
Each mark is a filing or an event in one; the bigger square is a 10-K. Hover for what it is, click to open it.
All 61 events
- Nov 9, 2026 Planned sale Ian Mortimer (President and Chief Executive Officer) adopted a trading planreported in the 10-Q
- Nov 9, 2026 Planned sale Thomas P. Kelly (Chief Financial Officer) adopted a trading planreported in the 10-Q
- Nov 9, 2026 8-K Quarterly results, Regulation FD disclosure8-K items 2.02, 7.01
- Nov 9, 2026 10-Q Quarterly report (10-Q)period ended Sep 30, 2026
- Oct 1, 2026 Buy MORTIMER IAN (PRESIDENT & CEO) bought $1.1Mopen-market purchase on Sep 30, 2026
- Oct 1, 2026 Buy Kelly Thomas Patrick (Chief Financial Officer) bought $560Kopen-market purchase on Sep 30, 2026
- Aug 28, 2026 Planned sale CHRISTOPHER KENNEY (Officer) gave notice of a planned sale of 7,068 shares worth about $438KForm 144, approximate sale date Aug 28, 2026, under a 10b5-1 plan adopted May 29, 2026
- Aug 13, 2026 Planned sale STEVEN GANNON (Director) gave notice of a planned sale of 10,000 shares worth about $641KForm 144, approximate sale date Aug 11, 2026
- Aug 6, 2026 Planned sale Dr. Christopher Kenney (Chief Medical Officer) adopted a 10b5-1 trading planreported in the 10-Q, up to 26,418 shares
- Aug 6, 2026 Planned sale Andrea DiFabio (Chief Legal Officer) adopted a 10b5-1 trading planreported in the 10-Q, up to 25,402 shares
- Aug 6, 2026 8-K Quarterly results, Regulation FD disclosure8-K items 2.02, 7.01
- Aug 6, 2026 10-Q Quarterly report (10-Q)period ended Jun 30, 2026
- Jun 5, 2026 Planned sale GARY PATOU (Director) gave notice of a planned sale of 1,322 shares worth about $70KForm 144, approximate sale date Jun 5, 2026, under a 10b5-1 plan adopted Aug 17, 2025
- Jun 5, 2026 Planned sale GILLIAN CANNON (Director) gave notice of a planned sale of 1,190 shares worth about $63KForm 144, approximate sale date Jun 5, 2026, under a 10b5-1 plan adopted Aug 15, 2025
- Jun 3, 2026 8-K Director or officer change, Shareholder vote results8-K items 5.02, 5.07
- May 7, 2026 8-K Quarterly results, Regulation FD disclosure8-K items 2.02, 7.01
- May 7, 2026 10-Q Quarterly report (10-Q)period ended Mar 31, 2026
- Apr 13, 2026 8-K Director or officer change8-K item 5.02
- Mar 13, 2026 Planned sale IAN MORTIMER (Officer, Director) gave notice of a planned sale of 7,308 shares worth about $404KForm 144, approximate sale date Mar 13, 2026, under a 10b5-1 plan adopted Dec 3, 2025
- Mar 13, 2026 Planned sale ANDREA DIFABIO (Officer) gave notice of a planned sale of 1,342 shares worth about $74KForm 144, approximate sale date Mar 13, 2026, under a 10b5-1 plan adopted Dec 3, 2025
- Mar 13, 2026 Planned sale CHRISTOPHER JOHN KENNEY (Officer) gave notice of a planned sale of 1,410 shares worth about $78KForm 144, approximate sale date Mar 13, 2026, under a 10b5-1 plan adopted Dec 3, 2025
- Mar 13, 2026 8-K Other events8-K item 8.01
- Mar 12, 2026 Offering Sale of 10.5M new shares424B5 · We are offering 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase 877,194 common shares in this offering.
- Mar 12, 2026 8-K Material agreement signed, Other events8-K items 1.01, 8.01
- Mar 10, 2026 Planned sale IAN MORTIMER (Officer, Director) gave notice of a planned sale of 11,269 shares worth about $677KForm 144, approximate sale date Mar 10, 2026, under a 10b5-1 plan adopted Dec 3, 2025
- Mar 10, 2026 Planned sale CHRISTOPHER JOHN KENNEY (Officer) gave notice of a planned sale of 2,771 shares worth about $167KForm 144, approximate sale date Mar 10, 2026, under a 10b5-1 plan adopted Dec 3, 2025
- Mar 10, 2026 Planned sale ANDREA DIFABIO (Officer) gave notice of a planned sale of 2,607 shares worth about $157KForm 144, approximate sale date Mar 10, 2026, under a 10b5-1 plan adopted Dec 3, 2025
- Mar 9, 2026 Planned sale IAN MORTIMER (Officer, Director) gave notice of a planned sale of 270,000 shares worth about $16.3MForm 144, approximate sale date Mar 9, 2026, under a 10b5-1 plan adopted Sep 27, 2024
- Mar 9, 2026 8-K Regulation FD disclosure8-K item 7.01
- Feb 27, 2026 Offering At-the-market program: up to $400M of common stock424B5 · In accordance with the terms of the Sales Agreement, we may offer and sell our common shares, without par value, or the Shares, from time to time through Jefferies and Stifel, acting as sales agents.
- Feb 27, 2026 8-K Other events8-K item 8.01
- Feb 26, 2026 Planned sale Andrea DiFabio (Chief Legal Officer and Corporate Secretary) adopted a 10b5-1 trading planreported in the 10-K
- Feb 26, 2026 Planned sale Christopher Kenney (Chief Medical Officer) adopted a 10b5-1 trading planreported in the 10-K
- Feb 26, 2026 Planned sale Darren Cline (Chief Commercial Officer) adopted a 10b5-1 trading planreported in the 10-K
- Feb 26, 2026 Planned sale Ian Mortimer (President and Chief Executive Officer) adopted a 10b5-1 trading planreported in the 10-K
- Feb 26, 2026 Planned sale Thomas P. Kelly (Chief Financial Officer) adopted a 10b5-1 trading planreported in the 10-K
- Feb 26, 2026 Auditor Auditor changed: KPMG LLP → PricewaterhouseCoopers LLPauditor named in the 10-K
- Feb 26, 2026 8-K Quarterly results, Regulation FD disclosure8-K items 2.02, 7.01
- Feb 26, 2026 10-K Annual report (10-K)period ended Dec 31, 2025
- Jan 2, 2026 Planned sale IAN MORTIMER (Officer, Director) gave notice of a planned sale of 40,000 shares worth about $1.8MForm 144, approximate sale date Jan 2, 2026, under a 10b5-1 plan adopted Sep 27, 2024
- Dec 8, 2025 Planned sale IAN MORTIMER (Officer, Director) gave notice of a planned sale of 10,830 shares worth about $495KForm 144, approximate sale date Dec 8, 2025, under a 10b5-1 plan adopted Sep 27, 2024
- Dec 5, 2025 Planned sale IAN MORTIMER (Officer, Director) gave notice of a planned sale of 14,375 shares worth about $647KForm 144, approximate sale date Dec 5, 2025, under a 10b5-1 plan adopted Sep 27, 2024
- Dec 1, 2025 Planned sale IAN MORTIMER (Officer, Director) gave notice of a planned sale of 97 shares worth about $4KForm 144, approximate sale date Nov 28, 2025, under a 10b5-1 plan adopted Sep 27, 2024
- Dec 1, 2025 8-K Director or officer change8-K item 5.02
- Nov 3, 2025 Planned sale Dr. Gillian Cannon (Board of Directors) adopted a 10b5-1 trading planreported in the 10-Q
- Nov 3, 2025 Planned sale Dr. Gary Patou (Board of Directors) adopted a 10b5-1 trading planreported in the 10-Q
- Nov 3, 2025 8-K Quarterly results, Regulation FD disclosure8-K items 2.02, 7.01
- Nov 3, 2025 10-Q Quarterly report (10-Q)period ended Sep 30, 2025
- Oct 17, 2025 8-K Director or officer change, Other events (amended)8-K items 5.02, 8.01
- Oct 16, 2025 8-K Director or officer change8-K item 5.02
- Aug 11, 2025 8-K Quarterly results, Regulation FD disclosure8-K items 2.02, 7.01
- Aug 11, 2025 10-Q Quarterly report (10-Q)period ended Jun 30, 2025
- Jul 3, 2025 8-K Director or officer change8-K item 5.02
- Jun 5, 2025 8-K Shareholder vote results8-K item 5.07
- May 12, 2025 8-K Quarterly results, Regulation FD disclosure8-K items 2.02, 7.01
- May 12, 2025 10-Q Quarterly report (10-Q)period ended Mar 31, 2025
- Mar 17, 2025 8-K Other events8-K item 8.01
- Mar 5, 2025 Auditor Auditor change8-K item 4.01
- Feb 27, 2025 Officer CFO changeSherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.
- Feb 27, 2025 10-K Annual report (10-K)period ended Dec 31, 2024
- Jan 17, 2025 8-K Director or officer change8-K item 5.02
From the SEC filing index. Insider purchases go back 180 days (the Form 4s downloaded).
Every filing
Newest first, by kind · each form links to sec.gov
| Filed | Form | What it is |
|---|---|---|
| Nov 9, 2026 | S-8 | Shares registered for employee plans |
| Nov 9, 2026 | 10-Q | Quarterly report |
| Nov 9, 2026 | 8-K | Quarterly results, Regulation FD disclosure |
| Nov 6, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Nov 6, 2026 | SCHEDULE 13G | 5%+ owner (passive) |
| Nov 5, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Oct 16, 2026 | 4 | Insider trade |
| Oct 1, 2026 | 4 | Insider trade |
| Oct 1, 2026 | 4 | Insider trade |
| Sep 3, 2026 | 4 | Insider trade |
| Aug 31, 2026 | 4 | Insider trade |
| Aug 28, 2026 | 144 | Notice of planned insider sale |
| Aug 13, 2026 | 4 | Insider trade |
| Aug 13, 2026 | 144 | Notice of planned insider sale |
| Aug 13, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Aug 7, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Aug 6, 2026 | 10-Q | Quarterly report |
| Aug 6, 2026 | 8-K | Quarterly results, Regulation FD disclosure |
| Aug 6, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| Jun 8, 2026 | 4 | Insider trade |
| Jun 8, 2026 | 4 | Insider trade |
| Jun 5, 2026 | 144 | Notice of planned insider sale |
| Jun 5, 2026 | 144 | Notice of planned insider sale |
| Jun 3, 2026 | 4 | Insider trade |
| Jun 3, 2026 | 4 | Insider trade |
| Jun 3, 2026 | 4 | Insider trade |
| Jun 3, 2026 | 4 | Insider trade |
| Jun 3, 2026 | 4 | Insider trade |
| Jun 3, 2026 | 4 | Insider trade |
| Jun 3, 2026 | 4 | Insider trade |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 POS | |
| Jun 3, 2026 | S-8 | Shares registered for employee plans |
| Jun 3, 2026 | 8-K | Director or officer change, Shareholder vote results |
| May 15, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| May 15, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| May 15, 2026 | SCHEDULE 13G/A | 5%+ owner (passive), amended |
| May 13, 2026 | 4 | Insider trade |
| May 7, 2026 | 10-Q | Quarterly report |
| May 7, 2026 | 8-K | Quarterly results, Regulation FD disclosure |
| Apr 22, 2026 | ARS | Annual report to shareholders |
| Apr 22, 2026 | DEFA14A | Extra proxy material |
| Apr 22, 2026 | DEF 14A | Proxy statement |
| Apr 13, 2026 | S-8 | Shares registered for employee plans |
| Apr 13, 2026 | 8-K | Director or officer change |
| Mar 13, 2026 | 4 | Insider trade |
| Mar 13, 2026 | 4 | Insider trade |
| Mar 13, 2026 | 4 | Insider trade |
| Mar 13, 2026 | 144 | Notice of planned insider sale |
| Mar 13, 2026 | 144 | Notice of planned insider sale |
| Mar 13, 2026 | 144 | Notice of planned insider sale |
| Mar 13, 2026 | 8-K | Other events |
| Mar 12, 2026 | 8-K | Material agreement signed, Other events |
| Mar 12, 2026 | 424B5 | Prospectus |
| Mar 11, 2026 | 4 | Insider trade |
| Mar 11, 2026 | 4 | Insider trade |
| Mar 11, 2026 | 4 | Insider trade |
| Mar 11, 2026 | FWP | Offering terms |
| Mar 10, 2026 | 144 | Notice of planned insider sale |
| Mar 10, 2026 | 144 | Notice of planned insider sale |
| Mar 10, 2026 | 144 | Notice of planned insider sale |
| Mar 9, 2026 | 424B5 | Prospectus |
| Mar 9, 2026 | 144 | Notice of planned insider sale |
| Mar 9, 2026 | 8-K | Regulation FD disclosure |
| Feb 27, 2026 | 8-K | Other events |
| Feb 27, 2026 | 424B5 | Prospectus |
| Feb 26, 2026 | 10-K | Annual report |
| Feb 26, 2026 | 8-K | Quarterly results, Regulation FD disclosure |
| Feb 10, 2026 | SCHEDULE 13G | 5%+ owner (passive) |
| Jan 9, 2026 | 4 | Insider trade |
| Jan 9, 2026 | 4 | Insider trade |
| Jan 9, 2026 | 4 | Insider trade |
| Jan 9, 2026 | 4 | Insider trade |
| Jan 2, 2026 | 4 | Insider trade |
| Jan 2, 2026 | 144 | Notice of planned insider sale |
| Dec 9, 2025 | 4 | Insider trade |
| Dec 8, 2025 | 144 | Notice of planned insider sale |
| Dec 5, 2025 | 144 | Notice of planned insider sale |
| Dec 3, 2025 | 4 | Insider trade |
| Dec 1, 2025 | 144 | Notice of planned insider sale |
| Dec 1, 2025 | S-8 | Shares registered for employee plans |
| Dec 1, 2025 | 8-K | Director or officer change |
| Nov 14, 2025 | SCHEDULE 13G | 5%+ owner (passive) |
| Nov 3, 2025 | 10-Q | Quarterly report |
| Nov 3, 2025 | 8-K | Quarterly results, Regulation FD disclosure |
| Oct 17, 2025 | 4 | Insider trade |
| Oct 17, 2025 | 3 | New insider |
| Oct 17, 2025 | 8-K/A | Director or officer change, Other events |
| Oct 16, 2025 | 8-K | Director or officer change |
| Oct 1, 2025 | 4 | Insider trade |
| Oct 1, 2025 | 144 | Notice of planned insider sale |
| Sep 19, 2025 | 144 | Notice of planned insider sale |
Show the other 75 filings on this page
Press releases with quarterly results are attached to the 8-Ks marked "Quarterly results"; read them on Earnings releases.
Sources
SEC's filing index (data.sec.gov submissions). Each form links to the document on sec.gov.
Also
Earnings releases: the text of each quarter's results release. Statements by period: the income statement, balance sheet or cash flow of the last filings side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XENE/export.csv") into a cell.